Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion

Author:

Layne Jennifer E.1,Parkin Christopher G.2,Zisser Howard1

Affiliation:

1. Insulet Corporation, Billerica, MA, USA

2. CGParkin Communications, Inc, Boulder City, NV, USA

Abstract

Background: Continuous subcutaneous insulin infusion (CSII) treatment with a tubeless patch pump has not been previously evaluated in a large cohort of patients. Methods: This multisite, retrospective study evaluated glycemic control in patients with type 1 diabetes (n = 873) after 3 months treatment the Omnipod® insulin management system (Insulet Corporation, Billerica, MA) compared to prior treatment with multiple daily injections (MDI) (78.1%) or CSII (21.9%). The primary outcome was change in HbA1c from baseline at 3 months post–Omnipod treatment initiation. Secondary outcomes included shifts in HbA1c to target levels, change in total daily dose (TDD) of insulin and in the frequency and severity of hypoglycemic episodes. Results: HbA1c was significantly improved at 3 months post–Omnipod treatment for the total population (mean ± SD): −0.6% ± 1.3 ( P < .001). HbA1c was also significantly lower compared to MDI: −0.3% ± 1.3, −0.4% ± 1.4, −0.8% ± 1.3 and −0.6% ± 1.3 ( P = .002 to P < .001) and CSII: −0.3% ± 0.8, −1.1% ± 1.6 ( P < .01), −0.4% ± 1.1 ( P < .001), and −0.5% ± 1.1 ( P < .001) for pediatric, adolescent, adult, and total populations, respectively. There was a 37.9% change increase in the proportion of patients ≥18 years and a 39.3% change increase in those <18 years achieving ADA treatment targets ( P = .004 to P < .001). There was a 16.4% change decrease in TDD of insulin at 3 months for the total population ( P < .001). The frequency of self-reported hypoglycemia decreased significantly ( P < .001) by 1.0 ± 2.4 episodes per week. Conclusions: Treatment with the Omnipod insulin management system was associated with clinically meaningful and statistically significant improvement in glycemic control, reduction in daily insulin requirement and reduction in the frequency and severity of hypoglycemic episodes.

Publisher

SAGE Publications

Subject

Biomedical Engineering,Bioengineering,Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3